Market Research Logo

Trigeminal Neuralgia - Pipeline Review, H2 2016

Trigeminal Neuralgia - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Trigeminal Neuralgia - Pipeline Review, H2 2016’, provides an overview of the Trigeminal Neuralgia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Trigeminal Neuralgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Trigeminal Neuralgia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Trigeminal Neuralgia
    • The report reviews pipeline therapeutics for Trigeminal Neuralgia by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Trigeminal Neuralgia therapeutics and enlists all their major and minor projects
    • The report assesses Trigeminal Neuralgia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Trigeminal Neuralgia
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Trigeminal Neuralgia
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Trigeminal Neuralgia pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Trigeminal Neuralgia Overview
    Therapeutics Development
    Pipeline Products for Trigeminal Neuralgia - Overview
    Pipeline Products for Trigeminal Neuralgia - Comparative Analysis
    Trigeminal Neuralgia - Therapeutics under Development by Companies
    Trigeminal Neuralgia - Therapeutics under Investigation by Universities/Institutes
    Trigeminal Neuralgia - Pipeline Products Glance
    Clinical Stage Products
    Early Stage Products
    Unknown Stage Products
    Trigeminal Neuralgia - Products under Development by Companies
    Trigeminal Neuralgia - Products under Investigation by Universities/Institutes
    Trigeminal Neuralgia - Companies Involved in Therapeutics Development
    Allergan Plc
    Biogen Inc
    KPI Therapeutics, Inc.
    Merz Pharma GmbH & Co. KgaA
    Trigemina, Inc.
    Trigeminal Neuralgia - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    (clonidine hydrochloride + naltrexone hydrochloride) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    incobotulinumtoxin A - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NeuroRelease TN - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    onabotulinumtoxin A - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    oxytocin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    raxatrigine hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigeminal Neuralgia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    U-2902 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Trigeminal Neuralgia - Dormant Projects
    Trigeminal Neuralgia - Product Development Milestones
    Featured News & Press Releases
    Jun 27, 2016: PixarBio Promotes David Kaplan to Chief Commercial Officer, as NeuroRelease a Morphine Strength Non Addictive Pain Treatment Remains on Track for 2018 Launch
    Mar 30, 2016: PixarBio, the Developers of NeuroRelease A Revolutionary Morphine Strength, Non-Addictive Pain Treatment Appoints Glenn Reiser Vice President of External Affairs
    Mar 03, 2016: PixarBio's Dr. Taunia Markvicka and Glenn Reiser to Discuss Breakthrough Data on Morphine Strength Non-Addictive Pain Treatment NeuroRelease at the 2016 Congress of Neurological Surgeons Spine Summit held in Orlando, FL March 17-18, 2016
    Nov 30, 2015: PixarBio's Glenn Reiser to Present Data on NeuroRelease, a Breakthrough Non-opiate and Non-addictive Pain Platform, at the 2015 Life Sciences Summit in New York, NY
    Oct 26, 2015: PixarBio Announces USFDA OPD Submission of NeuroRelease TN for Orphan Drug Designation for Trigeminal Neuralgia
    Sep 23, 2014: Convergence Pharmaceuticals' Novel Nav1.7 Selective Sodium Channel Blocker CNV1014802 Demonstrates Proof of Concept in Second Neuropathic Pain Study in Lumbosacral Radiculopathy
    Jun 16, 2014: Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study
    Jul 30, 2013: Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802
    Apr 23, 2013: Convergence Pharma Announces Successful Interim Data From Phase II Trigeminal Neuralgia Study
    Mar 27, 2013: Convergence Pharma Reports Positive Interim Data From Phase II Trigeminal Neuralgia Study Of CNV-1014802
    Mar 19, 2012: Convergence Initiates Phase II Study For CNV1014802 For Trigeminal Neuralgia
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Trigeminal Neuralgia, H2 2016
    Number of Products under Development for Trigeminal Neuralgia - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Comparative Analysis by Unknown Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Trigeminal Neuralgia - Pipeline by Allergan Plc, H2 2016
    Trigeminal Neuralgia - Pipeline by Biogen Inc, H2 2016
    Trigeminal Neuralgia - Pipeline by KPI Therapeutics, Inc., H2 2016
    Trigeminal Neuralgia - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2016
    Trigeminal Neuralgia - Pipeline by Trigemina, Inc., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Trigeminal Neuralgia - Dormant Projects, H2 2016
    List of Figures
    Number of Products under Development for Trigeminal Neuralgia, H2 2016
    Number of Products under Development for Trigeminal Neuralgia - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Targets, H2 2016
    Number of Products by Stage and Targets, H2 2016
    Number of Products by Mechanism of Actions, H2 2016
    Number of Products by Stage and Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report